Swallowed Batteries Should Be Removed to Avoid Stomach Damage: Study
2:00 PM CDT.
By Amy NortonHealthDay Reporter Read article
- Love the Smell of a Cup o’ Joe? Here’s What That Reveals About You
- For Women With HIV, Daily Life Can Impede Fight Against Virus
- AHA News: Drummer’s Death Inspires Grief-Stricken Bandmates to Rethink Rock ‘n’ Roll Lifestyle
- When E-Cig Makers Offer Promotional Items, More Teens Likely to Vape
JOURNAL UPDATE
Pool Chemical Injuries Led to ~13,500 ED Visits in 2015-2017
7:00 PM CDT. More than one-third of injuries occurred among patients aged younger than 18 years- Prenatal Care App Can Reduce In-Person Obstetric Visits
- Colorectal Cancer Incidence Increasing in Younger Adults
- Heroin Overdose ED Visits Decreased From 2017 to 2018
MONTHLY JOURNAL SUMMARY
April 2019 Briefing - Pharmacy
May 01, 2019. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
Ted Lain, MD.
Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…
Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Elizabeth M. Swisher, MD.
Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
MEDICAL FOCUS
Alzheimer’s disease
By Tamer M. Fouad, M.D.Alzheimer’s disease (AD) is the most common cause of dementia in Western countries.
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By MrRobinGreat articles. learnt a lot from it.
ANNOUNCEMENTS
Sunday Times - Doctors Lounge Voted top 10 best ‘Ask an expert’ website
Times Online / The Sunday Times voted Doctors Lounge as 3rd best ‘Ask an expert’ website.
